Introduction
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a clinically important and potentially lethal genetic disorder characterized by exercise/stress-induced ventricular arrhythmias including ventricular tachycardia and fibrillation (VT-VF) [1] [2] [3] [4] . The principal autosomal dominant form is caused by mutations in the RYR2-encoded cardiac ryanodine receptor while the rare autosomal recessive form stems from homozygous or compound heterozygous mutations in the CASQ2-encoded calsequestrin 2 gene (CASQ2), which both result in a net increase in intracellular, diastolic calcium during sympathetic activation [5] [6] [7] [8] [9] . CPVT manifests primarily in children and adolescents, and the ECG at rest is normal.
-blockers are effective in most patients 3 but when breakthrough events occur or when patients continue to manifest VT on exercise, clinical management becomes complex.
Furthermore, implantable cardioverter-defibrillators (ICDs), often useful in other arrhythmogenic disorders, can actually become part of the problem. Indeed, ICDs have not prevented sudden death in several patients, often because of exhausted therapies following arrhythmic storms or inappropriate discharges triggered by supraventricular tachycardias 10, 11 . Recently, preliminary data have suggested the potential value of combination drug therapy involving -blockers and flecainide, but definitive evidence is still lacking 12, 13 .
In 2008, we demonstrated that left cardiac sympathetic denervation (LCSD) had been quite effective in 3 CPVT patients who continued to suffer VF and aborted cardiac arrest (ACA) despite full-dose -blockers 14 . Our report was followed by others [15] [16] [17] [18] but, because of small numbers and limited follow-up, the most recent guidelines, while regarding LCSD as promising, still maintain that "its place in the management of CPVT remains to be proven" and relegate it to Class IIb status 19 . We felt the responsibility of following up on the initial study 14 and of -blockers are effective in most patients 3 but when breakthrough events oc oc occu cu cur r r or or or w w whe he hen n n patients continue to manifest VT on exercise, clinical management becomes complex.
Furt the he herm rm rmor or ore, e, e, imp mp mpla la lantable cardioverter-defibrilla a ato to tor rs s s (ICDs), often usef f ful ul ul in other arrhythmogenic d di diso o orders, can a a ac c ctu uall ll lly y y be be beco co come me me p pa a art t t of of of th he p pr r rob b blem m. Ind d dee ee eed, d, d, I I ICD CD CDs s ha ha have ve ve no ot p p pre re rev ve vent nt nted ed ed s s su u udde de den n n de e eat at ath h h in sev v ver er eral p p pa at a ien n nts s, s oft ten en en b b bec c cau au ause e e o o of ex ex xh ha haust ted d d th h he er erap ap pie ies fo fo follow ow owin n ng arrh rh rhyt yt ythmic ic ic storm rm ms or r r n n nap ap appr pr prop op opri ri riat at ate e e di di disc sc scha ha harg rg rges es es t t tri ri rigg gg gger er ered ed ed by b by s s sup p upra ra rave e vent nt ntri ri ricu c cula la lar r r ta ta tach ch chyc c ycar ar ardi di dias as as 10, 10, ,11 11 . Re Re Rece ce cent nt ntly l ly, pr pr prel el elim im imin in inar ar ary quantifying the efficacy of LCSD in an international study involving a sufficiently large number of CPVT patients to allow a definitive assessment of its role.
Methods

Study population
The study population consists of 63 patients with CPVT from 53 families who underwent LCSD between 1988 and 2014 at 11 centers worldwide: 6 in Europe, 2 in the USA, 1 each in Canada, Israel, and Australia. De-identified baseline and follow-up information were obtained by the coordinating center in Pavia using web-based forms. The diagnosis of CPVT was clinically based and/or genetically confirmed by the identification of a pathogenic CPVT-associated mutation in the proband and family members. The clinical features of these patients were overall similar to those described by Hayashi et al in their 101 CPVT patients 3 ; the only difference being that all events occurred earlier in our population, as expected by the much greater presence of severely symptomatic patients.
Patients were considered "symptomatic" if they had suffered at least one major cardiac event (MCE), i.e. either arrhythmic syncope, ACA, or ICD appropriate discharges (ICD-ADs).
Electrical storms were defined as the occurrence of 3 or more separate episodes of sustained ventricular VT/VF in 24 hours in patients without ICD, or 3 or more non-consecutive ICD shocks within 24-hours in patients with an ICD. An "end-of-treatment" condition was a series of consecutive ICD shocks leading to device therapy exhaustion.
All therapies, including drugs, ICD and LCSD, were prescribed at the discretion of each patient's physician. -blockers and/or flecainide at the maximum tolerated dose represented optimal medical treatment (OMT). Based on the "intention to treat" principle, MCEs after LCSD based and/or genetically confirmed by the identification of a pathogenic CPVT-as as sso so soci ci ciat at ated ed ed mutation in the proband and family members. The clinical features of these patients were overall imi ila la lar r r to to to t t tho ho hose d d de es escribed by Hayashi et al in the e eir ir ir 1 1 101 CPVT patients 3 ; ; ; th th the only difference being h h hat t t all events oc oc occu urr rr re ed ed e e ear ar arl l lie e er r r in in in o o ou ur ur p p pop pul l lat a a io o on, a as s ex xpe pe pe t ct cted ed ed by y the he he m m muc u u h h gr r rea ea eat te ter r r pr pr pres s sen en ence ce ce o o of f f e e eve ve vere r r ly sym ym ympt p p om m mat a ic p patient nt nts.
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Early follow-up for a few patients has been reported [14] [15] [16] [17] [18] .
Surgery
The interventions were performed over a 26-year period (from 1988 to 2014). Complete LCSD required resection of the lower half of the left stellate ganglion (T1) together with the thoracic ganglia T2-T4. This surgical denervation provides adequate cardiac denervation with no or minimal Horner's syndrome because most of the sympathetic fibers directed to the ocular region usually cross the upper portion of the left stellate ganglion and thus are spared. Whenever T1 or T4 were not ablated, denervation was considered incomplete. The main surgical approaches used were the thoracoscopic 16 , the transaxillary 17 , and the supraclavicular approach 20 .
Written informed consent was obtained for all patients according to local rules.
Statistical Analysis
Continuous data are presented as median with both the 25 th and 75 th percentiles which define the interquartile range (IQR). Absolute and relative frequencies were reported for categorical variables and compared by Fisher exact test. Non-parametric McNemar and Wilcoxon signed rank tests for correlated samples were used to analyze the effect of LCSD on morbidity and on cardiac event count, respectively. To account for varying observation times, the incidence rate of MCEs both pre-and post-LCSD was computed by dividing the total number of cardiac events by the total amount of follow-up duration of all patients and expressed as the average number (and 95% CI) of MCEs per patient/year of follow-up. To assess the effect of LCSD on the rate of events, while controlling for sex and age at surgery (</ 15 years), a negative binomial regression model was fitted, given the skewness in the frequency of MCEs, using generalized estimating T4 were not ablated, denervation was considered incomplete. The main surgical a a app pp ppro ro roac ac ache he hes s s us us used were the thoracoscopic 16 , the transaxillary 17 , and the supraclavicular approach 20 .
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Clinical History Before LCSD
No Cardiac Events
Nine (14%) asymptomatic patients, all CPVT1, underwent LCSD. In 8 of them, a positive family history for SCD and/or syncope was present, three also had minor documented ventricular arrhythmia (NSVT in 1 case, PVC's and bidirectional couplets in another, non-sustained broad complex tachycardia in the third) on therapy and two were intolerant to -blockers due to 
Cardiac events
Fifty-four patients were symptomatic before LCSD and most of them (n=38, 70%) continued to experience MCEs despite OMT. The median age at onset was 8.5 (IQR 6-11) years and by age 15, 96% of these symptomatic patients had already had a first MCE (Figure 1) . "Syncope only" occurred in 21 patients while 33 had ACA (n=18) and/or ICD-AD (n=23), usually in addition to one or more syncopal episodes. Electrical storms (n=14) and end-of-treatment conditions (n=4) also occurred.
Medical Therapy
Most patients (61/63, 97%) were on -blockers at the maximum tolerated dose at the time of LCSD. Other antiarrhythmic drugs, mostly flecainide (n=13) and mexiletine (n=5), were used in addition to -blockers in 26 patients (41%, Table 1 ). Two siblings were on flecainide monotherapy, without -blockers, because of sinus bradycardia.
Among the 54 symptomatic patients there were non-significant differences (79% vs 62%, p=0.24) when comparing the recurrences in patients receiving either nadolol or propranolol (22/28) vs other -blockers (16/26) .
ICD
An ICD was implanted in 37/63 patients (59%) at a median age of 11 (IQR 9-14. Amon on ong th h he e e 54 sy ym y pt tom om omat a a ic c c p p pat tie ie ien nt n s t t the e ere we we ere no o on-s -s sig g gni n n f f fic ca cant nt nt d d dif ff fere e enc nc ces ( (79 79 79% vs vs s 62% % %, , , p p p=0 0 0.24 24 24) ) ) wh h when en en c c com om ompa pa pari ri ring ng ng t t the he he r r rec ec ecur r urre re renc nc nces es es i i in n n pa pa pati ti tien en ents ts ts r r rec ec ecei ei eivi i ving ng ng e e eit it ithe he her r r n n nad ad adol ol olol ol ol o o or r r pr pr prop op opra ra rano no nolo lo lol l l (2 (2 (22/ 2/ 2/28 28 28) ) ) ) r r r years, there was a total of 17 device-related complications in 12/37 patients (32%), including 1 sepsis, 1 endocarditis, and 1 deep venous thrombosis. The majority (10/17, 59%) were cases of lead malfunctioning/fracture. In addition, 7 (19%) patients had a total of 10 generator replacements due to end-of-battery-life.
Of 
LCSD Surgery
The main indication for LCSD was the occurrence of breakthrough events while on OMT, and this occurred in 38 patients (60%). Among these patients, 25 (66%) had syncope, 7 (18%) had ACA, and 23 (61%) experienced 1 ICD-ADs. LCSD was performed as additional protection in the remaining 25 subjects, including the 9 asymptomatic patients. Median age at LCSD was 15 years (IQR [11] [12] [13] [14] [15] [16] [17] with no difference between symptomatic and asymptomatic patients. The approaches were mostly thoracoscopic (45, 71%) and supraclavicular (13, 21%), and LCSD was complete (from T1 to T4) in the majority of patients (n=56, 89%). In 7 patients (11%), only a partial denervation was performed: T1 was spared in 6 patients and T4 in 1. There was only 1 serious adverse event: 1 VF during surgery.
Clinical History After LCSD
LCSD and cardiac events in the study population 
LCSD Surgery
The e ma ma main in in i i ind nd ndic i at t tio io ion n for LCSD was the occurrence ce ce o o of f breakthrough event nt nts s while on OMT, and this o o occu cu curred in 38 p p pa at a i ient nt nts s s (6 (6 (60% 0% 0%). ). ). A A Am mo mong n n t th hese p p pa a atien nts s s, 25 5 5 (6 (6 (66% 6% 6%) ha ha had d d sy sync nc ncop pe, Figure 4 shows the overall effect of LCSD on the number of events in these 54 patients.
LCSD in patients with MCEs despite OMT
For the main efficacy analysis, we focused on the most seriously affected subgroup, the 38 patients who before LCSD continued to have MCEs despite OMT. The impact of LCSD on morbidity and on the incidence of cardiac events was equally remarkable in this high risk subset of non-responder OMT (n=16) were observed for a median follow-up of 39 months (IQR 27-64). Th h hei ei eir r r 1-1-1-a a and nd nd 2 2 2 y -y -yea f cumulative event-free survival was 87% and 81%, respectively (Figure 3 Table 2 shows that LCSD was associated with a remarkable reduction in both the percentage of symptomatic patients, from 100% to 32% (p<0.001), and in the mean annual rate of events per patient which dropped by 92% (p<0.001), from 3.4 (95% CI 3.2-3.7) to 0.5 (95% CI 0.4-0.6), while the median pre-and post-observation times were similar (51 months from institution of OMT to LCSD and 43 months post-LCSD follow-up, respectively).
We did consider some potential confounders: the burden of arrhythmic events prior to LCSD and changes in medical therapy. To address the first issue, we performed 2 different sensitivity analyses to evaluate the effect of LCSD on the event count. In the first, we excluded the 3 patients with an annual incidence rate >30 MCEs before LCSD (Fig. 5) and observed that the magnitude of the protective effect of LCSD was somewhat diminished but remained substantial and significant (a 78.5% reduction in the rate of MCEs when event rates after and before LCSD are compared, p<0.001). In the second, absolute numbers of MCEs >25 for a given patient were counted as 25 (n=9 patients). Also in this case, a remarkable reduction (88%) of MCEs post LCSD was observed.
We also considered that changes in medical therapy after LCSD might have contributed to its success rate. Table 3 shows that both the type and dose of -blockers remained essentially the same after surgery. The only change was an increase in the number of patients receiving flecainide, from 9 pre-to 16 post-LCSD. Of these additional 7 patients, 2 received flecainide in absence of MCEs while 5 because of continued recurrences. In only one of these 5 patients flecainide was associated with suppression of arrhythmic events.
LCSD and ICD
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Extent of denervation and outcome
Among the 54 symptomatic patients, the 7 subjects with an incomplete denervation were much 
Discussion
The present study provides evidence that LCSD plays a major role in the management of CPVT by markedly reducing the probability of life-threatening events, which unavoidably improves the quality of life of these young patients and of their families. Following the first report on the use 11 with MCEs on OMT, the post-LCSD percentage of patients with MCEs is 9% % ( ( (1/ 1/ 1/11 11 11). ). ).
Extent of denervation and outcome
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on on on t t the he he e e ext t xten en ent t t of of of d d den en ener er erva a vati ti tion on on p p per er erfo fo form rm rmed ed ed was as as e e eva a valu l luat at ated ed ed a a amo mo mong ng ng t t the he he 3 3 38 8 8 pa pa pati ti tien en ents ts ts wit it ith h h MC MC MCEs Es Es whi hi hile le le of LCSD in CPVT 14 , we thought necessary to document whether or not LCSD should become a recommended treatment for CPVT patients with numbers adequate to draw definitive conclusions.
Given the rarity of CPVT and the fact that LCSD is a procedure performed in only a limited number of centers, the present data on 63 such patients are reassuring and objectively impressive. The results are based on a strong rationale 21 and match those already observed in other arrhythmogenic conditions 18, [22] [23] [24] . These findings should, therefore, importantly impact on the approach to the management of CPVT.
Our analysis focused on the 54 patients who had previously suffered life-threatening events and who clearly represent a high-risk group. Among these, 38 patients (70%) continued to have recurrences despite OMT before LCSD, and 76% of those implanted with an ICD continued to have ICD-ADs at the disquieting rate of 3.6 shocks/patient/year. LCSD had a clear impact on all cardiac events, as 76% of the patients remained free of MCEs. The only patient who died during follow-up was the one who was switched suddenly from nadolol to metoprolol, despite the evidence of high risk for arrhythmic recurrences with this specific -blocker in the long QT syndrome (LQTS) 25 .
LCSD was associated with major reductions both in the number of patients with MCEs and in the actual number of MCEs. The impact of LCSD is clearly evident by the internal control analysis ( Figure 5 ) where each patient served as his/her own control and which shows a 92% reduction in MCEs. There was also a major reduction in the number of ICD-ADs; interestingly, this reduction ( 93%) is the same previously reported after LCSD for electrical storms in de de desp sp spit it ite e e th th the e e ev e evid id iden en ence ce ce o o of f f hi hi high gh gh r r ris is isk k k fo fo for r r ar ar arr r rhy h hyth th thmi mi mic c c re re recu c curr rr rren en ence ce ces s s wi i with th th t t thi hi his s s sp sp spec ec ecif if ific ic ic r r r b b -blo lo lock ck cker er er i i in n n th th the e e arrhythmia frequency; however, the reduction in MCEs following LCSD remains very high even after the sensitivity analyses performed to decrease the impact of a few outliers. Also, the results
were not influenced by changes in medical therapy as both doses and types of -blockers remained substantially stable when comparing the pre-and post-LCSD periods.
The concept of "therapeutic dose" is confirmed also for LCSD. Indeed, the 7 patients with an incomplete denervation, mostly caused by sparing the lower half of the left stellate ganglion, had significantly more recurrences of arrhythmic events compared to patients who received what is considered the comprehensive LCSD (T2-T4 plus a lower-half stellectomy).
This finding, reported in LQTS patients as well 22 , should mandate comprehensive LCSD and dissuade the execution of a suboptimal surgical procedure.
The antiarrhythmic and antifibrillatory effect of LCSD in a variety of clinical conditions, and its mechanisms of action, have been reviewed recently 21 . Critically important are the interruption of the localized release of norepinephrine at ventricular level which accentuates the arrhythmogenic ventricular dishomogeneity of repolarization 26 and its direct antifibrillatory effect 27 . Being a pre-ganglionic denervation, LCSD is not followed by reinnervation nor by postdenervation hypersensitivity 28 . Alpha-adrenergic antagonism may contribute to the favorable effects of LCSD in agreement with experimental findings in a model of calsequestrin-dependent CPVT 29 . Bilateral sympathectomy could be considered following only partial success with unilateral LCSD, to further reduce the release of norepinephrine at ventricular level and to better control heart rate 30 .
The present data force a reassessment of the current clinical approach to CPVT patients.
-blockers (propranolol or nadolol) certainly should remain first-line therapy, being effective for the majority (two-thirds) of patients 3 . Although reported as promising 12, 13, 19 , the combination of inappropriate shock) or contributes to these tragic deaths rather than providing the intended therapeutic solution 10, 11 . This potential unintended/undesired consequence is further compounded by an extremely high rate of adverse events: the 7-year incidence of complications (32%) and of generator replacements (19%) observed in our population is worrisome given the expected duration of treatment exceeding 50 years in these young patients. Careful ICD programming is necessary in CPVT because the effectiveness of appropriate shocks critically depends on the arrhythmia mechanism, being effective usually only when the treated rhythm is VF 31, 32 . Thus, CPVT patients with arrhythmic events despite -blockers are in dire need of an effective adjunct therapy. The present data conclusively indicate that LCSD represents a viable and effective answer to this predicament. As a one-time, minimally invasive procedure, LCSD is an effective anti-fibrillatory/antiarrhythmic intervention for patients with CPVT.
of death, the ICD usually saves lives but it does not represent an ideal solution for or r C C CPV PV PVT T T patients. Indeed, ICD shocks, by causing pain and fear, increase catecholamine release and could nitia ia ate te te e e ele le lect ct ctri ri r cal l l st st storms whereby the ICD actua all ll lly y y c c causes the death (in n th th the setting of an initial n n nap p ppropriate sh h hoc oc o k) ) ) o o or co co con nt ntri ri ribu bu but t te es e t t to th t these tr t a a agic c d d death th ths s s ra a ath th her r t t tha ha an n pr pr prov ov o idin n ng g g th th the e e in in inte e en n nded ed ed h h he er e ap ap apeutic so so solut ti t o on o 10, ,11 . . . This is is p p pot o o en n nti t t al l l u u uni n nt nt nten n nded d/u u unde de des sire e ed co o on n nseq eq eque u u nc n nce is is s f f fu u urther er er com mp p poun n nd ded by b by a a an n n ex e extr tr trem em emel el ely hi hi high gh gh r r rat at ate e e of of of a a adv d dver er erse se se e e eve e vent nt nts: s: s: t t the he he 7 7 7-ye e year ar ar i i inc nc ncid id iden en ence ce ce o o of f f co co comp mp mpli li lica ca cati ti tion on ons s s (3 (3 (32% 2% 2%) ) ) an an and d d of of of f LCSD should always be considered in CPVT patients experiencing recurrent ICD shocks.
The occurrence of major events post-LCSD in only 9% of the patients left without ICD despite life-threatening arrhythmias on OMT suggests that, in CPVT patients with syncope despite OMT, LCSD should be considered instead of proceeding directly to an ICD.
Limitations
We do not have a comparison group. In a disease such as CPVT, as it has been in the past the case for LQTS, a randomized clinical trial is simply not feasible for obvious reasons including ethical issues. The option to compare the present results with the outcome in our CPVT patients without LCSD is voided by the attendant selection bias because such a group would be at much lower risk as all our "high-risk" patients now undergo LCSD. Our observational study with "internal controls", with numbers adequate for a rare disease and very similar observation times pre-and post-surgery should raise confidence in the data and is the best possible under the specific conditions of a life-threatening rare disease managed with a novel therapeutic strategy.
Also, the appropriateness of the ICD shocks was assessed by the enrolling centers as we had not instituted a centralized blinded assessment for ICD interrogation. We did not deem necessary to obtain specific details for every patient as we were dealing with tertiary referral centers for arrhythmic patients with highly experienced electrophysiologists.-
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